Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's Phase 3 semaglutide Alzheimer's trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback